BrainCo seeks Hong Kong IPO with $280m for consumer brain tech

BrainCo, a prominent Chinese neurotech company, has confidentially filed for a Hong Kong stock exchange listing. The Hangzhou-based firm has raised approximately 2 billion yuan, or $280 million, in funding co-led by IDG Capital. It is viewed as a cornerstone of the city's "six little dragons," a cluster of startups symbolising China's tech ambitions.

Rather than competing in the surgical race dominated by Elon Musk’s Neuralink, BrainCo builds external wearables. Headbands and caps read electrical signals through the scalp, a lower-risk approach the company is using to bridge medicine and consumer electronics. Founded in 2015 at Harvard Innovation Labs, the company has deliberately avoided invasive brain implants.

Its medical credibility rests on FDA-approved bionic hands that translate an amputee's neural and muscular signals into finger movements. The company then carries those same sensors into everyday consumer products. One example is a sleep aid that delivers low-intensity electrical pulses aimed at neurochemicals associated with stress relief.

This non-invasive route already dominates the Chinese market, accounting for roughly 82% of domestic brain-computer interface sales. While American implant developers rely primarily on billionaire backers, BrainCo benefits from state coordination. China has a seven-ministry national plan targeting key BCI breakthroughs by 2027, having already approved the world's first commercial brain implant.

The commercialisation of wearable brain tech brings urgent regulatory questions for Europe. Because these devices do not require a surgeon, they remove a primary gatekeeper that traditionally limits who accesses neural technology. "We will never take brain implants beyond healthcare," Neuralink rival Inbrain has said, but BrainCo's business model depends entirely on mass-market consumer adoption.

The risks of uncontrolled deployment were demonstrated in 2019. A primary school in Zhejiang used BrainCo’s Focus headbands to score pupils' attention levels for teachers. "The devices were used in school trials to improve learning efficiency and had not been sold to any public school," BrainCo said after a fierce public backlash prompted the local education bureau to halt the trial.

Neural data represents a uniquely intimate category of information. As companies like BrainCo pivot from clinical devices to everyday consumer wearables, European policymakers face mounting pressure. They must establish explicit boundaries for commercial neural data collection before the technology scales globally, a regulatory gap that current frameworks do not adequately address.